March 22, 2006 |
Sanofi-Aventis and Bristol-Myers Squibb Co. said they had settled a dispute with generic drug maker Apotex Inc. that could keep patent protection on their multibillion-dollar blood thinner Plavix until 2011. A trial involving the disputed Plavix patent had been set to begin in June in U.S. District Court in New York. Sanofi and Bristol-Myers said they had approached Indian generic drug maker Dr. Reddy's Laboratories Ltd. to discuss a similar settlement.
July 21, 2001 |
British drug maker Bioglan Pharma might pay as much as $700 million for Bristol-Myers Squibb Co.'s skin-care unit, the Financial Times said, citing people close to the talks. Bioglan would only say it's considering an acquisition. A spokesman at Bristol-Myers said the company doesn't comment on rumors or speculation as a matter of policy. The drugs from Bristol-Myers would make Bioglan one of the top five companies in the $8.6-billion market for dermatology products, analysts said.
August 16, 2002 |
Shares of Bristol-Myers Squibb Co. fell after the pharmaceutical maker disclosed that it may have to restate results because it had encouraged wholesalers to buy too many drugs as a way to pad its revenue. In a securities filing, Bristol-Myers also stated that a probe by the Securities and Exchange Commission into the overstocking issue might become "a more formal investigation." The SEC is investigating the sales promotion to see if it inflated Bristol-Myers 2001 earnings by up to $1 billion.
October 19, 2002 |
Bristol-Myers Squibb Co. settled a lawsuit filed by Walgreen Co., Safeway Inc. and other chain pharmacies over its efforts to block generic competition to its anti-anxiety drug BuSpar. J.C. Penney Co.'s Eckerd drugstores, Kroger Co. and Albertson's Inc. also were plaintiffs in the lawsuit, filed in New York in April. Bristol-Myers is in talks to settle a similar group of lawsuits filed by consumers. A company spokesman said details are confidential.
September 4, 2002 |
Bristol-Myers Squibb Co. moved closer to Food and Drug Administration approval of the Abilify schizophrenia drug, which may be the company's next big product. The drug maker said it is in discussions with the FDA, which sent a letter indicating that the product may be approved after certain issues are resolved. The company didn't reveal what concerns the FDA raised in the letter. Bristol-Myers said it expects FDA approval of Abilify this year.
December 13, 2008 |
Bristol-Myers Squibb Co. and Sanofi-Aventis won an appeals court ruling Friday that will help them block generic competition to the blood thinner Plavix, the world's No. 2 selling-drug, in the U.S. until 2011. Bristol-Myers and Sanofi said that as a result of the ruling by a three-judge panel of the U.S. Court of Appeals for the Federal Circuit in Washington, they will seek reimbursement from Canadian drug maker Apotex Inc.
June 29, 2004 |
Bristol-Myers Squibb Co. said it would set aside an additional $400 million, mostly to cover potential liabilities from a U.S. probe of its inventory practices and accounting. The increase would be reflected as a second-quarter expense, New York-based Bristol-Myers said. The company set aside $250 million last year for legal matters.
December 24, 2004 |
Bristol-Myers Squibb Co., a drug maker with patents set to expire on four medicines by 2010, said it asked U.S. regulators to approve its once-daily diabetes drug Muraglitazar. If approved, the drug will be sold jointly by Bristol-Myers and Merck & Co., which announced Sept. 30 that it would pull its Vioxx painkiller from the market. Merck in April agreed to pay Bristol-Myers as much as $375 million to share the rights to Muraglitazar. Shares of Bristol-Myers rose 28 cents to $25.83 on the NYSE.
April 30, 2003 |
Bristol-Myers Squibb Co., the drug maker that last month restated earnings back to 1999, said first-quarter profit fell 11% as costs rose and generic rivals eroded sales of some former top sellers. Net income at the fourth-biggest U.S. drug maker slipped to $761 million, or 39 cents a share, from $856 million, or 44 cents, a year earlier. Sales rose 1% to $4.71 billion, the New York-based firm said.